Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-31. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Membrane blebbing: The cell membrane shows irregular buds known as blebs. Initially these are smaller surface blebs. Later these can grow into larger so-called dynamic membrane blebs. An important regulator of apoptotic cell membrane blebbing is ROCK1 (rho associated coiled-coil-containing protein kinase 1). Formation of membrane protrusions: Some cell types, under specific conditions, may develop different types of long, thin extensions of the cell membrane called membrane protrusions. Three types have been described: microtubule spikes, apoptopodia (feet of death), and beaded apoptopodia (the latter having a beads-on-a-string appearance). Pannexin 1 is an important component of membrane channels involved in the formation of apoptopodia and beaded apoptopodia. Fragmentation: The cell breaks apart into multiple vesicles called apoptotic bodies, which undergo phagocytosis. The plasma membrane protrusions may help bring apoptotic bodies closer to phagocytes.
date-range is the range of dates corresponding to the given confidence level confidence indicates the confidence level for the given date range. For example, "cal 1220–1281 AD (1σ)" means a calibrated date for which the true date lies between AD 1220 and AD 1281, with a confidence level of '1 sigma', or approximately 68%. Calibrated dates can also be expressed as "BP" instead of using "BC" and "AD". The curve used to calibrate the results should be the latest available IntCal curve. Calibrated dates should also identify any programs, such as OxCal, used to perform the calibration. In addition, an article in Radiocarbon in 2014 about radiocarbon date reporting conventions recommends that information should be provided about sample treatment, including the sample material, pretreatment methods, and quality control measurements; that the citation to the software used for calibration should specify the version number and any options or models used; and that the calibrated date should be given with the associated probabilities for each range.
In another one-pot multicomponent reaction, a unique two-carbon expansion has been achieved by reacting isatin with indene-1,3-dione and N-substituted pyridinium bromide to form dibenzo[b,d]azepin-6-ones.
Sources: en.wikipedia.org
For services to British Business in South-East Asia. John Worsley Knagg, Director, British Council English Language Centre, Singapore. Lam Shiu-kum. For services to medicine in Hong Kong. Gerald John Laving. For services to British business interests, and to the community, in Russia. Ranee Lee Pui-Leung, . For public and community service in Hong Kong. Shelly Lau Lee Lai-kuen, . Director of Home Affairs, Hong Kong. Edmund Kwong Ho Leung. For services to engineering in Hong Kong. Jurek Martin, Washington Bureau Chief, Financial Times. Patrick Joseph McGuinness, lately First Secretary, British Embassy, Abu Dhabi. Evelyn Hugh Norie. For services to British business interests in Hong Kong. Alan Richardson, , Director, Accounting Services, Hong Kong. Rolf Schild. For public and industrial services. Michael John Steere. For services to British engineering in Norway. Ian Robert Strachan, , Director of Social Welfare, Hong Kong. Robert Wallace. For services to British commercial interests overseas. Michael David Williams, Rabbi to the Copernic community in Paris. David Wong Shou-yeh, . For services to business and the community, Hong Kong. The Honourable Samuel Wong Ping-wai, . For public services, Hong Kong. William John Woods. For services to community health care in Brazil. Raymond Wu Wai-yung. For services to psychiatric rehabilitation in Hong Kong. Helen Yu Lai Ching-ping, , Director of Education, Hong Kong.
The classification of spironolactone as a "potassium-sparing diuretic" has been described as obsolete. Spironolactone is also used to treat Bartter's syndrome due to its ability to raise potassium levels. Spironolactone, which has antiandrogenic effects, may help improve acne in adult women, with modest benefits demonstrated in recent clinical trials. Its use is limited by short-term outcome data and minimal reporting of side effects. It is considered a possible alternative to antibiotics for hormonal acne. It is also used to manage other androgen-related conditions such as hirsutism, seborrhoea, and female pattern hair loss Spironolactone is used for the treatment of hirsutism in the United States. High doses of spironolactone, which are needed for considerable antiandrogenic effects, are not recommended for men due to the high risk of feminization and other side effects. Spironolactone can be used to treat symptoms of hyperandrogenism, such as due to polycystic ovary syndrome.
=== Collection of data from phylogenetic trees === For each branch in the phylogenetic trees of the protein families, the number of mismatches that were observed were recorded and a record kept of the two amino acids involved. These counts were used as entries below the main diagonal of the matrix
Sources: en.wikipedia.org
In some countries, ayahuasca is a forbidden or controlled or regulated substance, while in other countries it is not a controlled substance or its production, consumption, and sale, is allowed to various degrees.
== Critical reception == After the airing of the second season, many have categorized Blue Ridge as a sleeper hit. The series began on INSP only, before streaming providers began to air the series. Pluto TV, Amazon Prime Video and Roku have all seen the show rise into their Top 10 most watched programs, more so with the second season. On Amazon, the series at times traded places with the blockbuster TV show, Reacher. The series has received steady reviews on IMDb with an overall rating of 6.6. Positive reviewers praise it as entertaining, family-friendly viewing built around a single father raising his daughter alongside his ex-wife's family, and describe him as dealing with some PTSD. On Amazon, it has received a 4.4 out of 5 rating.
== Unrelated words in -omics == The word "comic" does not use the "omics" suffix; it derives from Greek "κωμ(ο)-" (merriment) + "-ικ(ο)-" (an adjectival suffix), rather than presenting a truncation of "σωμ(ατ)-". Similarly, the word "economy" is assembled from Greek "οικ(ο)-" (household) + "νομ(ο)-" (law or custom), and "economic(s)" from "οικ(ο)-" + "νομ(ο)-" + "-ικ(ο)-". The suffix -omics is sometimes used to create names for schools of economics, such as Reaganomics.
On 1 May 1989, the American Physical Society held a session on cold fusion in Baltimore, including many reports of experiments that failed to produce evidence of cold fusion. At the end of the session, eight of the nine leading speakers stated that they considered the initial Fleischmann and Pons claim dead, with the ninth, Johann Rafelski, abstaining. Steven E. Koonin of Caltech called the Utah report a result of "the incompetence and delusion of Pons and Fleischmann," which was met with a standing ovation. Douglas R. O. Morrison, a physicist representing CERN, was the first to call the episode an example of pathological science. On 4 May, due to all this new criticism, the meetings with various representatives from Washington were cancelled. From 8 May, only the A&M tritium results kept cold fusion afloat. In July and November 1989, Nature published papers critical of cold fusion claims. Negative results were also published in several other scientific journals including Science, Physical Review Letters, and Physical Review C (nuclear physics). In August 1989, in spite of this trend, the state of Utah invested $4.5 million to create the National Cold Fusion Institute. The United States Department of Energy organized a special panel to review cold fusion theory and research. The panel issued its report in November 1989, concluding that results as of that date did not present convincing evidence that useful sources of energy would result from the phenomena attributed to cold fusion.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.